Table S8. Prognostic effect of the copy number of genomic regions. Multivariate results in optimal quality samples only.
| Chr | Region ID | CNA frequency | Disease-free survival | Overall survival | Lung-cancer specific survival | Mb | Genes | cytoBands | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Losses | Gains | HR for loss* (95% CI) | HR for gain** (95% CI) | P | HR for loss* (95% CI) | HR for gain** (95% CI) | P | Q | HR for loss* (95% CI) | HR for gain** (95% CI) | P | ||||||||
| 3 | 72 | 1.8% | 44.8% | 2.4 (1.6–3.5) | 0.42 (0.28–0.63) | <0.001 | 2.8 (1.8–4.4) | 0.35 (0.23–0.55) | <0.001 | 2.5 (1.6–3.8) | 0.40 (0.26–0.62) | <0.001 | 5.0E+0 | MECOM | q26.1–2 | ||||
| 9 | 211 | 34.8% | 3.4% | 2.4 (1.7–3.3) | 0.43 (0.30–0.60) | <0.001 | 2.8 (1.9–4.1) | 0.36 (0.24–0.53) | <0.001 | 3.0E−1 | p21.3 | ||||||||
| 12 | 277 | 2.4% | 14.9% | 0.47 (0.27–0.81) | 2.1 (1.2–3.7) | 0.007 | 3.0E+0 | p11.21–1 | |||||||||||
| 17 | 354 | 2.7% | 10.3% | 0.45 (0.23–0.86) | 2.2 (1.2–4.3) | 0.016 | 0.41 (0.21–0.82) | 2.4 (1.2–4.9) | 0.012 | 2.0E−2 | q21.32 | ||||||||
| 19 | 396 | 4.6% | 10.5% | 0.64 (0.46–0.88) | 1.6 (1.1–2.2) | 0.006 | 2.0E−2 | q13.32 | |||||||||||
Results from a model adjuster by treatment arm, patient age, sex, performance status (PS), histology, T, and N stage. *, hazard ratio for a 2-fold lower copy number; **, hazard ratio for a 2-fold higher copy number.